TLDR
- DataMEDS AI (MEDS) closed up 87.20% at $1.62 after completing its acquisition of Helomics Corp. from Axe Compute (AGPU)
- The deal was valued at $1.5 million, structured through common stock and an acquisition note, with no third-party debt
- DataMEDS received Helomics’ CLIA/CAP-certified clinical lab, all equipment, the Predictive Oncology CRO business, and $1.5 million in cash
- The acquisition moves DataMEDS into the $40 billion U.S. cancer diagnostics and treatment market
- MEDS has a market cap of around $5 million and has fallen 97.64% over the past 12 months
DataMEDS AI (NASDAQ: MEDS) saw its stock close up 87.20% at $1.62 on Tuesday, following news that it completed its acquisition of Helomics Corporation from Axe Compute Inc. (NASDAQ: AGPU). The stock had surged as high as 66% in pre-market trading before extending gains through the regular session.
The deal was valued at $1.5 million total, paid through common stock and an acquisition note. DataMEDS took on no third-party debt as part of the transaction.
In return, DataMEDS received Helomics’ CLIA/CAP-certified clinical laboratory, full ownership of all lab equipment, the Predictive Oncology contract research organization (CRO) central lab services business, and $1.5 million in cash.
Helomics is based in Pittsburgh and uses artificial intelligence to analyze real-world tumor data. It supports drug discovery and cancer treatment decisions through functional precision medicine.
The acquisition gives DataMEDS a direct entry point into the U.S. cancer diagnostics and treatment market, which is estimated at around $40 billion.
Expanding Beyond GLP-1 and Long COVID
Gerald Commissiong, Interim Co-CEO of DataMEDS, said the deal pushes the company into oncology, with a focus on improving outcomes for patients in rural areas. He noted that DataMEDS plans to expand its services beyond GLP-1 agonist side effects and Long COVID into cancer diagnosis and treatment.
Under DataMEDS’ ownership, Helomics is expected to grow beyond tumor molecular profiling and chemosensitivity testing. Plans include cancer screening, traditional CLIA lab services, and nutritional support for cancer patients.
Axe Compute CEO Chris Miglino said the deal structure allows his company to keep a shareholder position in Helomics going forward. Axe Compute will now focus on scaling its core AI infrastructure business.
Helomics was the last remaining operating business from Axe Compute’s previous identity as Predictive Oncology Inc., before the company rebranded in December 2025.
By the Numbers
DataMEDS carries a market cap of roughly $5 million. Its 52-week high is $75 and its 52-week low is $0.82. The stock has dropped 97.64% over the past 12 months.
The RSI for MEDS stood at 56.10 at the time of reporting.
AGPU stock was up 2.74% on the day.
Further details on the transaction will be filed in a Current Report on Form 8-K with the SEC.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Be the first to comment